CSS LLC’s VYNE Therapeutics VYNE Stock Holding History

CSS LLC’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,341	Closed	-$3.62K	–	904
2022 Q4	$3.62K	Hold	1,341	–	–	﹤0.01%	854
2022 Q3	$5K	Sell	1,341 -63	-4%	-$403	﹤0.01%	1000
2022 Q2	$10K	Hold	1,404	–	–	﹤0.01%	1031
2022 Q1	$16K	Hold	1,404	–	–	﹤0.01%	1080
2021 Q4	$26K	Hold	1,404	–	–	﹤0.01%	1150
2021 Q3	$35K	Hold	1,404	–	–	﹤0.01%	1095
2021 Q2	$89K	Hold	1,404	–	–	﹤0.01%	953
2021 Q1	$173K	Sell	1,404 -208	-13%	-$30.2K	0.01%	786
2020 Q4	$183K	Sell	1,612 -139	-8%	-$17.5K	0.01%	649
2020 Q3	$209K	Hold	1,751	–	–	0.01%	567
2020 Q2	$218K	Buy	1,751 +1,127	+181%	+$153K	0.01%	481
2020 Q1	$120K	Buy	+624	New	+$196K	0.01%	480

Other funds holding VYNE

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SCA

STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

CSS LLC's VYNE Position: Q1 2023 in Review

CSS LLC sold out of VYNE Therapeutics (VYNE) in Q1 2023, closing a stake of 1,341 shares — an estimated $3.62K sold.

CSS LLC first reported a position in VYNE in Q1 2020 and held it in 12 quarters. The position peaked at $218K in Q2 2020. 23 funds tracked by Wall St. Rank hold VYNE as of Q1 2023.

CSS LLC reported no remaining VYNE Therapeutics position as of Q1 2023 after selling out during the quarter.
CSS LLC sold 1,341 VYNE Therapeutics shares in Q1 2023, an estimated $3.62K.
CSS LLC first reported a position in VYNE Therapeutics in Q1 2020 and held it in 12 quarters.
CSS LLC's VYNE Therapeutics position peaked at $218K in Q2 2020.
23 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2023.

Based on CSS LLC's 13F filing for Q1 2023, filed 15 May 2023.